SQLite Web: event_store.db

Update row sig_b707e7872aa7 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt","company":"Vivos Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_59c5ca074101877b","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:17:23.115016+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt","source_event_id":"evt_a19fac0d6bb3","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"e2ceafa4673122f4","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-16","2025-12-31","today at 5:00 pm ET"],"entities":[{"asset_class":"equity","name":"Vivos Therapeutics, Inc.","relevance":"high","symbol":"VVOS","type":"issuer"},{"asset_class":"equity","name":"Vivos","relevance":"high","symbol":"VVOS","type":"company_reference"},{"asset_class":"private_or_unknown","name":"The Sleep Center of Nevada","relevance":"medium","symbol":"","type":"business_entity"},{"asset_class":"government","name":"SEC","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"earnings","information_gaps":["The specific 8-K Item number(s) beyond Item 2.02 are not shown in the cleaned text beyond the mention of Item 9.01 (exhibits).","No detailed financial statement figures (e.g., net loss, cash balance, operating expenses) are included in the provided excerpt beyond the 16% revenue increase and qualitative statements about gross margin and investments.","The text does not include the prior known state needed to explicitly quantify what changed versus the prior filing; only the current filing\u2019s contents are provided.","The excerpt does not include the full conference call details (e.g., dial-in number) due to truncation."],"key_facts":["Filing is a Form 8-K with Item 2.02: Results of Operations and Financial Condition.","The 8-K states that on April 15, 2026, Vivos issued a press release announcing financial results for the fiscal year ended December 31, 2025.","The press release text is furnished as Exhibit 99.1 to the 8-K and incorporated by reference.","The furnished press release states full-year 2025 revenue increased 16%.","The press release states gross margin was maintained despite significant investment.","The press release attributes performance to ramp of sleep testing services and integration of The Sleep Center of Nevada.","The press release states management expects a path toward cash flow positive operations by end of this year (as stated in the provided text).","The press release states management will host a conference call at 5:00 p.m. Eastern time on the day of the release.","The 8-K includes standard language that the information is not deemed filed for purposes of Section 18 of the Exchange Act (as provided)."],"numeric_claims":[{"label":"Full-year 2025 revenue increase","value":"16%"}],"primary_claim":"On April 15, 2026, Vivos Therapeutics issued a press release announcing its financial results for the fiscal year ended December 31, 2025, furnished as Exhibit 99.1 to its Form 8-K.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Vivos Therapeutics, Inc. filed a Form 8-K on April 15, 2026 to report its full-year 2025 financial results via a furnished press release (Exhibit 99.1). The filing references Item 2.02 and highlights 16% full-year revenue growth and ongoing integration of The Sleep Center of Nevada.","topics":["Form 8-K","Item 2.02","full-year 2025 financial results","press release furnished as Exhibit 99.1","revenue growth","gross margin","sleep testing services ramp","integration of The Sleep Center of Nevada","business strategy pivot","conference call"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Vivos Therapeutics, Inc. \u00b7 Filed 20260415","ticker":"VVOS","tickers":["VVOS"],"title":"VVOS filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-016865.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel